<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unipolar depression in adults: Treatment with second-generation antipsychotics
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unipolar depression in adults: Treatment with second-generation antipsychotics
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unipolar depression in adults: Treatment with second-generation antipsychotics
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Craig Nelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H21954874">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second-generation antipsychotics are often indicated for unipolar major depression, as well as other psychiatric disorders such as schizophrenia and bipolar disorder. For major depression, atypical antipsychotics are used adjunctively for nonpsychotic patients who respond insufficiently to antidepressant monotherapy [
         <a href="#rid1">
          1,2
         </a>
         ]. Second-generation antipsychotics in combination with an antidepressant are also effective for psychotic depression [
         <a href="#rid3">
          3
         </a>
         ], and the atypical antipsychotic
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         is effective as monotherapy for nonpsychotic depression [
         <a href="#rid4">
          4
         </a>
         ]. The efficacy of atypical antipsychotics for major depression is hypothesized to be the result of their serotonergic, noradrenergic, and dopaminergic effects [
         <a href="#rid5">
          5-11
         </a>
         ].
        </p>
        <p>
         First-generation antipsychotics have also been used to treat depression, initially as monotherapy and subsequently as adjunctive treatment with an antidepressant [
         <a href="#rid12">
          12,13
         </a>
         ]. Randomized trials found that for nonpsychotic depression, first-generation antipsychotic monotherapy was superior to placebo and either comparable or superior to an antidepressant. However, the use of first-generation antipsychotics for depression has declined because of the risk of tardive dyskinesia, which is greater for first-generation than second-generation antipsychotics [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         This topic reviews the use of second-generation antipsychotics for treating unipolar major depression. The initial treatment of depression, treatment of resistant depression, clinical features and diagnosis of depression, and the pharmacology of second-generation antipsychotics are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H493149">
         <span class="h1">
          DEFINITION OF MAJOR DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         An episode of major depressive disorder (unipolar major depression) is defined in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a period lasting at least two weeks, with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, decreased energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. Additional information about the clinical features and diagnosis of unipolar major depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91774.html" rel="external">
          "Unipolar depression in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H493815">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In unipolar major depression, second-generation antipsychotics are indicated for patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonpsychotic depression that does not respond sufficiently to antidepressant monotherapy – the antipsychotic is generally added to the same antidepressant [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Patients who prioritize efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotic depression – the antipsychotic is started concurrently with an antidepressant [
         <a href="#rid16">
          16-18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">
          "Unipolar major depression with psychotic features: Acute treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In addition, the second-generation antipsychotic
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         may be efficacious as monotherapy for unipolar, nonpsychotic major depression, and thus an option when switching from an ineffective treatment regimen [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21954769">
         <span class="h1">
          ADJUNCTIVE TREATMENT FOR NONPSYCHOTIC DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjunctive medications are commonly used to treat unipolar nonpsychotic depression, because many patients respond insufficiently to antidepressant monotherapy [
         <a href="#rid1">
          1
         </a>
         ]. As an example, an open-label study of
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         in 3671 patients with major depression found that remission occurred in only 37 percent [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Among available adjunctive medications, many authorities and clinicians choose a second-generation antipsychotic. In a study of outpatient visits for antidepressant-treated, nonpsychotic unipolar depression (n &gt;2500), a second-generation antipsychotic was prescribed during 11 percent of the visits (20 percent of visits with psychiatrists and 5 percent of visits to other physicians) [
         <a href="#rid23">
          23
         </a>
         ]. The most commonly prescribed antipsychotics were
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         . Other choices for augmentation include
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ] and triiodothyronine (T
         <sub>
          3
         </sub>
         ) [
         <a href="#rid25">
          25
         </a>
         ]. Additional information about augmenting an antidepressant in treatment resistant depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Initial approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H430764">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of augmenting an antidepressant with a second-generation antipsychotic is established for acute treatment of major depression but not maintenance treatment [
         <a href="#rid2">
          2,26-28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H550095">
         <span class="h3">
          Acute phase
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefit of adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         for acute treatment of depression has been demonstrated in randomized trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2009 meta-analysis of 16 randomized trials compared the efficacy of add-on
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         with placebo in 3480 patients with major depressive disorder who failed monotherapy with an antidepressant [
         <a href="#rid2">
          2
         </a>
         ]. The study drug was added to the original, ongoing antidepressant in 14 of the trials; in 2 trials, the study drug and a new antidepressant were started concurrently. The trials generally lasted either six or eight weeks. Key findings included the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         More patients remitted with an antipsychotic than placebo (31 versus 17 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Discontinuation of treatment due to adverse effects was greater with an antipsychotic than placebo (9 versus 2 percent of patients). (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         were each superior to placebo, and no antipsychotic was superior to another.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A subsequent network meta-analysis replicated most of these findings [
         <a href="#rid29">
          29
         </a>
         ]. In addition, a subsequent randomized trial found that add-on
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         was beneficial for managing late-life, treatment resistant depression. (See
         <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">
          "Diagnosis and management of late-life unipolar depression", section on 'Aripiprazole'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent eight-week randomized trial compared add-on
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         with placebo in patients (n = 139) with major depression who did not respond to open-label treatment with
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) was greater with ziprasidone than placebo (35 versus 21 percent of patients). However, discontinuation of treatment due to adverse effects was greater with ziprasidone than placebo (14 versus 0 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another subsequent trial, lasting six weeks, compared adjunctive
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         with placebo in patients with major depression who did not respond to open-label treatment with antidepressant monotherapy (n = 353) [
         <a href="#rid31">
          31
         </a>
         ]. Response occurred in more patients who received add-on brexpiprazole than placebo (23 versus 16 percent). However, remission with brexpiprazole occurred in only 15 percent. Discontinuation of treatment due to adverse effects with active drug or placebo occurred in 3 and 0 percent. The same group of investigators conducted a second trial using similar methods, and the results were comparable [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent eight-week trial enrolled patients with unipolar major depression who, by history, had an inadequate response to at least six weeks of their current antidepressant; the patients were randomly assigned to add-on
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         2 to 4.5 mg/day (n = 271) or placebo (n = 264) [
         <a href="#rid33">
          33
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received cariprazine than placebo (49 versus 38 percent). However, discontinuation of treatment due to adverse events was greater with cariprazine than placebo (13 versus 3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study enrolled patients with late life depression and prospectively treated them with open-label
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         ; patients who did not remit (n = 181) were randomly assigned to add-on
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         or placebo for 12 weeks [
         <a href="#rid34">
          34
         </a>
         ]. Remission occurred in more patients who received aripiprazole than placebo (44 versus 29 percent). Discontinuation of treatment due to adverse events was only 3 percent in each group. Aripiprazole is the only adjunctive agent, of any type, shown to be effective in older adults in a randomized, placebo-controlled study. (See
         <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">
          "Diagnosis and management of late-life unipolar depression", section on 'Adjunctive medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         No head-to-head randomized trials have been conducted to determine whether there are differences in efficacy among adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         . However, secondary clinical effects may differentially affect the utility of adjunctive antipsychotics for treating major depression. As an example, quetiapine is sedating and useful for insomnia [
         <a href="#rid35">
          35
         </a>
         ], whereas olanzapine causes the most weight gain, which may help patients with anorexia and excessive weight loss. By contrast, ziprasidone does not lead to weight gain. Additional secondary (side) effects are discussed separately. (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         below.)
        </p>
        <p>
         It is reasonable to use an adjunctive antipsychotic with any antidepressant. In randomized trials, the antipsychotic was usually added to a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor [
         <a href="#rid2">
          2,30-33
         </a>
         ].
        </p>
        <p>
         Improvement of depressive symptoms with adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         largely occurred within the first two weeks of treatment [
         <a href="#rid35">
          35-39
         </a>
         ]. Thus, we suggest that clinicians wait at least this long before determining whether the drug is useful. Patients who improve less than 25 percent from baseline by week four of treatment are unlikely to respond further with longer treatment.
        </p>
        <p>
         No randomized, placebo controlled trials have evaluated
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9087" href="/z/d/drug information/9087.html" rel="external">
          iloperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">
          lurasidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         as adjunctive treatment for patients with unipolar, nonpsychotic major depression that has failed antidepressant monotherapy. However, these drugs are reasonable alternatives for patients who have failed or cannot tolerate
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         .
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          Clozapine
         </a>
         should be avoided because it can cause agranulocytosis.
        </p>
        <p>
         Although the efficacy of adjunctive second-generation antipsychotics such as
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         is clearly established, the magnitude of the benefit has been questioned. As an example, a review of three randomized trials that compared adjunctive quetiapine with placebo (n = 995 patients) concluded that the clinical effect was small and may not offset potential harms such as the metabolic syndrome [
         <a href="#rid40">
          40
         </a>
         ]. Nevertheless, the number needed to treat for quetiapine was nine, which means that adjunctive quetiapine provided one more remission than placebo for every nine patients treated with each regimen; many clinicians view this as clinically meaningful.
        </p>
        <p class="headingAnchor" id="H550103">
         <span class="h4">
          Minimal response to antidepressant compared with partial response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjunctive second-generation antipsychotics may be effective for patients with either a minimal response to antidepressant monotherapy or a partial response [
         <a href="#rid41">
          41
         </a>
         ]. Although it is commonly thought that augmentation is more useful to increase the improvement achieved in partial responders than in minimal responders [
         <a href="#rid42">
          42,43
         </a>
         ], this is not established. A pooled analysis of three randomized trials compared adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (2 to 20 mg per day) with placebo in patients with unipolar major depression who were initially treated eight weeks with open-label antidepressant monotherapy, and had either a minimal response (improvement from baseline on the depression rating scale &lt;25 percent) or partial response (improvement of 25 to 49 percent) [
         <a href="#rid44">
          44
         </a>
         ]. The primary findings after six weeks of adjunctive treatment were as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 746 patients with an initial minimal response, remission occurred in significantly more patients who received adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         than placebo (24 versus 12 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 292 patients with an initial partial response, remission was larger for adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         than placebo (41 versus 31 percent), but the difference was not statistically significant.
        </p>
        <p>
        </p>
        <p>
         In addition, adjunctive antipsychotics may benefit patients who worsen during initial treatment with antidepressant monotherapy [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H539368">
         <span class="h4">
          Comparisons with other adjunctive medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials that compared add-on second-generation antipsychotics with other add-on medications, for major depression that had failed antidepressant monotherapy, include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One open-label, six-week, randomized trial compared adjunctive
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (300 mg/day) with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (0.6 to 1.2 mmol/L) in patients (n = 450) with unipolar major depression who, by history, did not respond to at least one antidepressant [
         <a href="#rid46">
          46
         </a>
         ]. Remission with add-on quetiapine and add-on lithium was comparable (32 and 27 percent of patients). In addition, discontinuation of treatment due to adverse events appeared to be comparable with quetiapine and lithium (10 and 8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another open-label, six-week, randomized trial enrolled patients with unipolar major depression who by history, did not respond to at least four weeks of selective serotonin reuptake inhibitor treatment (n = 103), and randomly assigned them to
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (mean dose 3 mg/day) or
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         (mean dose 199 mg/day) [
         <a href="#rid47">
          47
         </a>
         ]. Although most outcomes were comparable for the two groups, remission occurred in more patients who received aripiprazole than bupropion (55 versus 34 percent). Discontinuation of treatment was comparable for aripiprazole and bupropion (25 versus 23 percent of patients), no patients discontinued treatment because of adverse events, and the incidence of extrapyramidal symptoms and of akathisia was comparable for the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third open-label trial, lasting 12 weeks, found that remission with either add-on
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         or add-on
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         was comparable [
         <a href="#rid48">
          48
         </a>
         ]. However, response (reduction of baseline symptoms ≥50 percent) was modestly greater with adjunctive aripiprazole (74 versus 66 percent), and withdrawal for lack of response with adjunctive aripiprazole was half of that for adjunctive bupropion (3 and 6 percent). This trial is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Efficacy of primary treatment strategies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The meta-analysis of 16 randomized trials (3480 patients with major depression) of adjunctive second-generation antipsychotics represents the most rigorous body of evidence for any type of adjunctive treatment in depression [
         <a href="#rid2">
          2
         </a>
         ]. By contrast, the nine randomized trials of adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         included only 237 depressed patients, many of whom would not meet current criteria for treatment resistance, and only three trials (n = 76 patients) used lithium to augment a second-generation antidepressant [
         <a href="#rid24">
          24
         </a>
         ]. Comparisons between lithium and other adjunctive agents are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13506.html" rel="external">
          "Unipolar depression in adults: Treatment with lithium", section on 'Compared directly with other drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H550119">
         <span class="h3">
          Maintenance phase
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unipolar major depression who have failed multiple treatment regimens and then responded to adjunctive second-generation antipsychotics that are well-tolerated, it is reasonable to continue the antipsychotic to prevent relapse. As an example, a 27-week randomized maintenance trial compared
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         (25 or 50 mg per day) plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         (6, 12, or 18 mg per day) with fluoxetine monotherapy in patients with treatment resistant depression who initially responded to acute and continuation treatment with open-label fluoxetine plus olanzapine (n = 444) [
         <a href="#rid49">
          49
         </a>
         ]. There were fewer recurrences in patients who received fluoxetine plus olanzapine than fluoxetine alone (16 versus 32 percent). However, adjunctive olanzapine caused more weight gain, and clinically significant weight gain (≥7 percent) in occurred in 56 percent of patients who received olanzapine in all three study phases (up to 47 weeks). Adverse changes in glucose, triglycerides, cholesterol, and prolactin also occurred more frequently with olanzapine plus fluoxetine.
        </p>
        <p>
         However, another randomized trial found no benefit for maintenance treatment with adjunctive second-generation antipsychotics. In the trial, patients with unipolar major depression unresponsive to
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         monotherapy (20 to 60 mg per day) were given open-label adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         (0.25 to 2 mg per day) [
         <a href="#rid26">
          26
         </a>
         ]. The patients who remitted or were much improved (n = 241) were treated for six months with citalopram plus risperidone or citalopram plus placebo; relapse rates for the two groups were comparable.
        </p>
        <p class="headingAnchor" id="H432190">
         <span class="h2">
          Safety issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefits of adjunctive second-generation antipsychotics need to be weighed against safety issues that include the metabolic syndrome, and the less common but serious problems of tardive dyskinesia and neuroleptic malignant syndrome (NMS).
        </p>
        <p class="headingAnchor" id="H9371665">
         <span class="h3">
          Metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight gain, diabetes, and hyperlipidemia are elements of the metabolic syndrome that can occur with second-generation antipsychotics, although the frequency of these problems appears to vary depending upon the specific drug that is used  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 2
         </a>
         ). Rates of the metabolic syndrome during randomized trials of adjunctive atypical antipsychotics in patients with unipolar major depression have not been reported [
         <a href="#rid35">
          35,50,51
         </a>
         ]. However, a meta-analysis of four observational studies with 1745 patients found that a higher rate of the metabolic syndrome was associated with use of antipsychotic medication [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Additional information about the metabolic side effects of antipsychotics is discussed separately in the context of schizophrenia. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Endocrinologic and metabolic side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Metabolic dysregulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H175304454">
         <span class="h4">
          Weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight gain was common during short-term randomized trials of adjunctive second-generation antipsychotics [
         <a href="#rid35">
          35,50,51
         </a>
         ], especially with
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . A pooled analysis of two adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         trials suggested that weight gain may be greater during combination treatment with an antidepressant in unipolar major depression, compared with weight gain reported in monotherapy trials in schizophrenia or bipolar disorder [
         <a href="#rid53">
          53
         </a>
         ]. However, one trial found that although patients with late life depression gained more weight with adjunctive aripiprazole than placebo, change in body fat was comparable for the two groups, suggesting cardiometabolic risk was not affected [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Long-term treatment may cause additional weight gain. In a randomized trial (n = 386), adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         caused weight gain ≥7 percent of body weight from baseline to end point of study phase in 3 percent of the patients during the initial 4- to 6-week open-label phase, and in another 8 percent of patients during the 24-week double-blind phase [
         <a href="#rid26">
          26
         </a>
         ]. It is worth mentioning that major depression may cause weight loss; thus, weight gain may be desirable in some patients.
        </p>
        <p class="headingAnchor" id="H1244492">
         <span class="h3">
          Tardive dyskinesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although tardive dyskinesia is less common with second-generation antipsychotics than first-generation antipsychotics  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ], it is still a concern because tardive dyskinesia may be irreversible, depressed patients may be at greater risk, and tardive dyskinesia is not associated with most other augmentation options. The risk of tardive dyskinesia with second-generation antipsychotics in unipolar major depression is not well established:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aripiprazole
         </strong>
         – A 52-week, open-label study of adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         in 994 patients with unipolar major depression found four cases of possible tardive dyskinesia that all resolved within 45 days of drug discontinuation [
         <a href="#rid54">
          54
         </a>
         ]. Without a control group, this rate may overestimate the rate of tardive dyskinesia due to drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brexpiprazole
         </strong>
         – In two 52-week, open-label studies of 2084 patients with unipolar major depression who were treated with adjunctive
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         , one case of oral-buccal dyskinesia was observed [
         <a href="#rid55">
          55
         </a>
         ]. The dyskinesia resolved 22 days after stopping the drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Olanzapine
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 12-week, randomized trial of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         in 259 patients with unipolar psychotic depression found that tardive dyskinesia occurred in 8 percent [
         <a href="#rid3">
          3
         </a>
         ]. However, it appears that this rate may have reflected prior antipsychotic use and very sensitive criteria rather than new cases of tardive dyskinesia [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No new cases of tardive dyskinesia were found in a 76-week open-label study of adjunctive
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         in 560 patients with unipolar major depression [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quetiapine
         </strong>
         – A 52-week, randomized monotherapy maintenance trial in 391 patients with unipolar major depression assigned to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         did not find evidence of tardive dyskinesia [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risperidone
         </strong>
         – Rates of tardive dyskinesia have not been reported for adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         in unipolar major depression during long term treatment [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional information about the risk of tardive dyskinesia with second-generation antipsychotics is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis", section on 'Causative agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H540929">
         <span class="h3">
          Neuroleptic malignant syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         NMS can occur with second-generation antipsychotics [
         <a href="#rid59">
          59,60
         </a>
         ]. However, rates of NMS for atypical antipsychotics are not established in part because of the large sample required to reasonably estimate the rate of a rarely occurring event. In addition, bias may exist in that an atypical agent is likely to be given to patients who require an antipsychotic and have a prior history of NMS. NMS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H86138377">
         <span class="h3">
          Suicidal thinking and behavior in young adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         The second-generation antipsychotics carry a class warning (product information in the United States) about a possible increased risk of suicidal ideation or suicide attempt in patients under the age of 25 years. However, this risk was not established in trials of atypical antipsychotics, and this risk may be reduced if adjunctive treatment is begun six to eight weeks after the patient has received an antidepressant. Second-generation antipsychotics may potentially be useful for treating suicidal ideation as well as symptoms such as agitation, anxiety, and insomnia, which may aggravate suicidal thinking and behavior.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A preplanned, pooled analysis of two randomized trials examined suicidal ideation in 936 patients (age 18 to 65 years) with major depression who did not respond sufficiently to antidepressant monotherapy and subsequently received adjunctive
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (150 mg or 300 mg per day) or placebo for six weeks [
         <a href="#rid35">
          35
         </a>
         ]. Treatment-emergent suicidal ideation occurred in more patients who received placebo than in those who received quetiapine (2.6 versus 0.6 and 1.0 percent; not tested statistically).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A post hoc, pooled analysis of two randomized trials examined suicidal ideation in 702 patients (age &gt;25 years) with major depression who did not respond sufficiently to antidepressant monotherapy and subsequently received adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (2 to 20 mg per day) or placebo for six weeks [
         <a href="#rid61">
          61
         </a>
         ]. Treatment-emergent suicidal ideation occurred in significantly more patients who received placebo than aripiprazole (relative risk 0.14, 95% CI 0.03-0.60).
        </p>
        <p>
        </p>
        <p>
         However, treatment emergent suicidality with adjunctive second-generation antipsychotics in unipolar major depression has not been well studied in patients who are under 25 years of age and at greatest risk.
        </p>
        <p class="headingAnchor" id="H540872">
         <span class="h2">
          Medication doses and side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of an adjunctive second-generation antipsychotic for nonpsychotic unipolar major depression is often lower than the dose used for schizophrenia or bipolar disorder [
         <a href="#rid31">
          31,32,36,37,62,63
         </a>
         ]. In addition, the methods used in randomized trials of adjunctive second-generation antipsychotics for major depression may suggest the need for doses that are higher than necessary. Clinicians may thus find that doses at the lower end of the range that was used in the trials are effective in many patients; higher doses can be reserved for patients with an inadequate response to the antipsychotic or severely ill patients requiring an especially fast response.
        </p>
        <p>
         Therapeutic serum concentrations have not been established for adjunctive second-generation antipsychotics in major depression and are not used to guide dosing. Nevertheless, serum concentrations of adjunctive antipsychotics may be affected by drug-drug interactions with an antidepressant. Conversely, the antipsychotics appear to have minimal effects on the clearance of other drugs. Specific interactions of second-generation antipsychotics with antidepressants may be determined using the
         <a class="external" href="/drug-interactions">
          Lexicomp drug interactions
         </a>
         tool (Lexi-Interact Online) included in UpToDate.
        </p>
        <p>
         Short-term use of adjunctive atypical antipsychotics for depression is usually well tolerated; however, randomized trials have found that discontinuation of treatment due to adverse effects was generally greater with antipsychotics than placebo. In a pooled analysis of 16 randomized trials involving adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         in 3480 patients with major depression who failed monotherapy with an antidepressant, withdrawal from the study because of side effects was higher in patients who received an antipsychotic compared with placebo (9 versus 2 percent) [
         <a href="#rid2">
          2
         </a>
         ]. Treatment of approximately 17 patients with the antipsychotic caused discontinuation in one additional patient that would not have occurred with placebo (number needed to harm of 17, which is generally regarded as not clinically significant [
         <a href="#rid64">
          64
         </a>
         ]). The drop-out rate due to side effects varied from 4 percent (aripiprazole) to 12 percent (quetiapine), but the differences among the four atypical antipsychotics were not statistically significant [
         <a href="#rid2">
          2
         </a>
         ]. In a subsequent randomized trial (n = 139 patients), discontinuation of treatment due to side effects was greater with add-on
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         than placebo (14 versus 0 percent) [
         <a href="#rid30">
          30
         </a>
         ]. However, in the two
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         trials, discontinuation rates due to adverse events were low for active drug and placebo (3 and 1 percent) [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         The side effect profile for each antipsychotic is different  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 2
         </a>
         ). As an example, studies of adjunctive second-generation antipsychotics for unipolar major depression suggest that the following drugs may be more likely to cause specific adverse effects [
         <a href="#rid65">
          65
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aripiprazole – akathisia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Olanzapine – weight gain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Quetiapine – sedation
        </p>
        <p>
        </p>
        <p>
         The sections below discuss the doses and side effects for
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , when used adjunctively for unipolar major depression. Additional information about the side effects of second-generation antipsychotics is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H432220">
         <span class="h3">
          Aripiprazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard dose of adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         for unipolar major depression ranges from 5 to 15 mg per day. However, patients may respond to lower doses; a randomized trial in Japanese patients found 3 mg per day effective [
         <a href="#rid66">
          66
         </a>
         ]. The most common side effect is akathisia, which is dose dependent.
        </p>
        <p>
         Doses of 5 to 20 mg per day for adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         were established in three randomized United States trials that lasted six weeks; 547 patients with major depression received active drug [
         <a href="#rid36">
          36,38,67
         </a>
         ]. Aripiprazole was started at 5 mg and increased each week by increments of 5 mg per day as clinically indicated, to a maximum of 20 mg per day. The mean final dose was 11 mg per day. A subsequent United States randomized trial (n = 225) found that adjunctive aripiprazole 2 mg per day was not beneficial [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         A subsequent six-week randomized trial compared adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         3 mg per day with placebo in Japanese patients with treatment resistant major depression (n = 392), and found that improvement was superior with aripiprazole [
         <a href="#rid66">
          66
         </a>
         ]. The difference in the efficacy of low dose aripiprazole between the United States trial and the Japanese trial may be explained by the greater prevalence of the 2D6*10 allele in Asian populations, which impairs metabolism via the CYP2D6 pathway and results in higher drug serum concentrations [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         In a pooled analysis of two randomized trials (n = 737) lasting six weeks, the following side effects occurred in more patients who received adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         5 to 20 mg per day than in patients who received placebo [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Akathisia (25 versus 4 percent of patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restlessness (12 versus 2 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia (8 versus 3 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blurred vision (6 versus 1 percent)
        </p>
        <p>
        </p>
        <p>
         The rate of akathisia in the two, fixed, low dose trials of
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         was as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         United States trial that compared
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         2 mg per day with placebo (15 versus 13 percent) [
         <a href="#rid68">
          68
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Japanese trial that compared
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         3 mg per day with placebo (14 versus 4 percent) [
         <a href="#rid66">
          66
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Mean weight gain in the two trials was also greater with adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         than placebo (1.7 versus 0.4 kg) [
         <a href="#rid50">
          50
         </a>
         ]. In an observational study of 994 patients with major depression who received adjunctive aripiprazole for up to 52 weeks, the mean weight gain was 4.4 kg [
         <a href="#rid54">
          54
         </a>
         ]. However, one randomized trial found that although patients with late life depression gained more weight with adjunctive aripiprazole than placebo, change in body fat was comparable for the two groups, suggesting cardiometabolic risk was not affected [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H310810593">
         <span class="h3">
          Brexpiprazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         for unipolar depression is 1, 2, or 3 mg per day; however, 2 and 3 mg may be more efficacious than 1 mg. The most common side effects include weight gain and akathisia.
        </p>
        <p>
         The dose of add-on
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         was established in two randomized trials that lasted six weeks; 599 patients received active drug [
         <a href="#rid31">
          31,32
         </a>
         ]. However, on certain outcome measures (eg, mean reduction of depression rating scale scores), the dose of 1 mg per day was not statistically different from placebo, whereas brexpiprazole 2 mg per day and 3 mg per day were. On other outcome measures (eg, proportion of patients who improved more than 50 percent from baseline), all three doses of brexpiprazole were superior to placebo.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          Brexpiprazole
         </a>
         is started at a dose of 0.5 mg per day for the first week of treatment, and is then titrated up to a dose of 1 mg per day for week two [
         <a href="#rid31">
          31,32
         </a>
         ]. Subsequently, the dose can be increased directly to either 2 mg per day or 3 mg per day.
        </p>
        <p>
         Weight gain during six weeks of treatment is greater with adjunctive
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         than placebo (approximately 1.5 versus 0.3 kg) [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          Brexpiprazole
         </a>
         also appears to cause dose-dependent akathisia [
         <a href="#rid31">
          31,32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placebo – 2 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          Brexpiprazole
         </a>
         1 mg/day – 4 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          Brexpiprazole
         </a>
         2 mg/day – 7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          Brexpiprazole
         </a>
         3 mg/day – 14 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1168058424">
         <span class="h3">
          Cariprazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The target dose of
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         is 1.5 to 3 mg/day [
         <a href="#rid70">
          70
         </a>
         ]; however, doses of 4.5 mg/day may be indicated [
         <a href="#rid33">
          33
         </a>
         ]. The most common side effects are akathisia, insomnia, and nausea [
         <a href="#rid33">
          33,70
         </a>
         ].
        </p>
        <p>
         The starting dose of adjunctive
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         is 1.5 mg/day [
         <a href="#rid33">
          33,70
         </a>
         ]. If patients do not show improvement after two weeks and are tolerating the drug, the dose can be titrated up to 3 mg/day. Depending upon response and tolerability, the dose can be increased to 4.5 mg/day; however, rates of akathisia up to 22 percent have been reported at this dose [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         was evaluated in an eight-week randomized trial, which enrolled patients with unipolar major depression (n = 819) who had an inadequate response to their current antidepressant; patients were randomly assigned to add-on cariprazine 1 to 2 mg/day, cariprazine 2 to 4.5 mg/day, or placebo [
         <a href="#rid33">
          33
         </a>
         ]. The mean daily dose in the lower cariprazine dose group was 1.4 mg/day, and in the higher dose group, 2.6 mg/day. Improvement of depression was greater with cariprazine 2 to 4.5 mg/day than placebo, whereas improvement with cariprazine 1 to 2 mg/day and placebo was comparable. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received cariprazine 2 to 4.5 mg/day or cariprazine 1 to 2 mg/day, compared with patients who received placebo (49 and 48 versus 38 percent).
        </p>
        <p>
         A six-week trial enrolled 757 patients with unipolar major depression who had an inadequate response to their antidepressant, and found that 1.5 mg of
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         added to their antidepressant was more effective than placebo, but 3.0 mg/day was not more effective [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Adverse effects observed with adjunctive
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         1.5 to 4.5 mg/day and placebo included the following [
         <a href="#rid33">
          33,71,72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Akathisia – 5 to 22 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia – 6 to 14 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea – 5 to 13 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue – 4 to 10 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somnolence – 5 to 10 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor – 2 to 8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight gain ≥7 percent of baseline weight – 2 to 3 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H432348">
         <span class="h3">
          Olanzapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         for unipolar major depression ranges from 5 to 20 mg per day. The most common side effect is weight gain.
        </p>
        <p>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         was established in five randomized trials that lasted 8 or 12 weeks; 639 patients with major depression received active drug [
         <a href="#rid51">
          51,62,73,74
         </a>
         ]. Olanzapine was generally started at 6 mg per day and increased every two weeks by increments of 6 mg per day as clinically indicated, to a maximum of 18 mg per day. The mean final dose was approximately 9 mg per day.
        </p>
        <p>
         In a pooled analysis of two randomized trials (n = 401), side effects that occurred in significantly more patients who received adjunctive
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         than in those who received placebo included [
         <a href="#rid51">
          51
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight gain (35 versus 7 percent of patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased appetite (32 versus 6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth (29 versus 9 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somnolence (18 versus 5 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral edema (12 versus 1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypersomnia (11 versus 2 percent)
        </p>
        <p>
        </p>
        <p>
         Compared with placebo, adjunctive
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         caused a significantly greater increase in [
         <a href="#rid51">
          51
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight (4.9 versus 0.4 kg)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolactin serum level (3.4 versus 0.9 mcg/L)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total cholesterol (15.1 versus 0.8 mg/dL)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H432355">
         <span class="h3">
          Quetiapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release for unipolar major depression is 300 or 150 mg per day. The 300 mg dose is slightly more efficacious, but discontinuation from treatment is nearly 75 percent higher [
         <a href="#rid35">
          35
         </a>
         ]. Use of the immediate release formulation is reasonable [
         <a href="#rid75">
          75
         </a>
         ]. The most common adverse effects with either formulation are dry mouth and sedation.
        </p>
        <p>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release was established in two randomized trials that lasted six weeks; 627 patients with major depression received a fixed dose of quetiapine extended release 150 or 300 mg per day [
         <a href="#rid35">
          35
         </a>
         ]. A trial of adjunctive quetiapine immediate release found that a mean dose of 182 mg per day was efficacious (29 patients received quetiapine) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         In a pooled analysis of two randomized trials (n = 936), side effects that occurred in more patients who received adjunctive
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release 300 or 150 mg per day than placebo included [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth (40 and 27 versus 8 percent of patients; not tested statistically)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somnolence (26 and 23 versus 4 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation (17 and 13 versus 4 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dizziness (12 and 11 versus 6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue (11 and 14 versus 4 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Constipation (11 and 6 versus 4 percent)
        </p>
        <p>
        </p>
        <p>
         Over six weeks, mean weight gain for adjunctive
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         300 mg per day was 1.3 kg, quetiapine 150 mg per day was 0.9 kg, and placebo was 0.2 kg (not tested statistically) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Hepatotoxicity due to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         has been reported [
         <a href="#rid76">
          76,77
         </a>
         ], including a fatal case in an older adult patient who received 25 mg per day for nine days to treat agitation and insomnia [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21954784">
         <span class="h3">
          Risperidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         for unipolar major depression ranges from 0.25 to 3 mg per day. The most common side effect is sedation and dry mouth, but both rates appear to be low.
        </p>
        <p>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         was established in three randomized trials that lasted between four and eight weeks; 213 patients with major depression received active drug [
         <a href="#rid37">
          37,79,80
         </a>
         ]. Risperidone was started at 0.25 or 0.5 mg per day and generally increased by increments of 0.25 to 1 mg per day every several days as clinically indicated; the usual final dose was 1 to 1.5 mg per day.
        </p>
        <p>
         In the largest randomized trial of adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         (n = 268), side effects that occurred in more patients who received risperidone than placebo included [
         <a href="#rid37">
          37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somnolence (5 versus 2 percent of patients; not tested statistically)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth (5 percent versus 1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight gain (4 percent versus 2 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia (4 percent versus 2 percent)
        </p>
        <p>
        </p>
        <p>
         Over six weeks, mean weight gain was higher with adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         than placebo (1.3 versus 0.1 kg; not tested statistically).
        </p>
        <p class="headingAnchor" id="H683773">
         <span class="h3">
          Ziprasidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of adjunctive
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         for unipolar major depression is 20 to 80 mg twice per day. The most common side effect is somnolence and fatigue.
        </p>
        <p>
         The dose of add-on
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         was established in an eight-week randomized trial; 71 patients with major depression who were treated with
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         received active drug [
         <a href="#rid30">
          30
         </a>
         ]. Ziprasidone was started at 20 mg twice per day and increased each week by 20 mg twice per day as clinically indicated to a maximum of 80 mg twice per day; following at least one dose increase, clinicians could lower the dose to address adverse side effects. The possible dose range was thus 20 to 80 mg twice per day and the total mean daily dose was approximately 100 mg per day.
        </p>
        <p>
         In the randomized trial (n = 139 patients), side effects that occurred in more patients who received adjunctive
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         than placebo included [
         <a href="#rid30">
          30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somnolence/fatigue (34 versus 12 percent of patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscle twitching (11 versus 1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritability (10 versus 1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety/agitation (6 versus 0 percent)
        </p>
        <p>
        </p>
        <p>
         In addition, weight gain was greater with active drug than placebo (3.5 versus 1.0 kg), and akathisia occurred in twice as many patients with
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         than placebo (15 versus 7 percent).
        </p>
        <p>
         It is not clear if
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         causes clinically meaningful QTc prolongation. The randomized trial excluded patients with significant cardiac conduction problems (eg, atrial fibrillation, atrioventricular block, or prolonged QTc or QRS intervals), as well as patients with abnormal serum concentrations of potassium or magnesium [
         <a href="#rid30">
          30
         </a>
         ]. There was a trend for a greater increase in QTc with ziprasidone than placebo (p = 0.06); ziprasidone led to a mean increase in QTc of 8.8 msec [
         <a href="#rid30">
          30,81
         </a>
         ]. One patient treated with adjunctive ziprasidone discontinued treatment due to a QTc interval &gt;500 msec.
        </p>
        <p class="headingAnchor" id="H494067">
         <span class="h1">
          COMBINATION TREATMENT FOR PSYCHOTIC DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unipolar major depression with psychotic features (ie, delusions or hallucinations) is often treated with an antidepressant plus an antipsychotic, which is consistent with practice guidelines [
         <a href="#rid16">
          16-18
         </a>
         ]. The acute and maintenance treatment of unipolar psychotic depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16546.html" rel="external">
          "Unipolar major depression with psychotic features: Acute treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16596.html" rel="external">
          "Unipolar major depression with psychotic features: Maintenance treatment and course of illness"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H433345">
         <span class="h1">
          MONOTHERAPY FOR NONPSYCHOTIC DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second-generation antipsychotic monotherapy may be efficacious for nonpsychotic unipolar major depression, and thus an option when switching from an ineffective treatment regimen. However, these drugs can cause many side effects  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 2
         </a>
         ), which are discussed separately. (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2410409989">
         <span class="h2">
          Lurasidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">
          Lurasidone
         </a>
         monotherapy may be beneficial for unipolar major depression with mixed features. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment", section on 'Depression with mixed features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H95248719">
         <span class="h2">
          Quetiapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
         monotherapy can provide a small benefit for patients with major depression:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of four randomized trials (lasting six or eight weeks) compared
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release (50, 150, or 300 mg per day) with placebo in 1752 patients with nonpsychotic unipolar major depression who were either untreated or did not respond satisfactorily to one antidepressant trial [
         <a href="#rid4">
          4
         </a>
         ]. Remission occurred in more patients who received quetiapine than placebo (37 versus 30 percent); quetiapine thus provided one more remission than placebo for every 15 patients treated with each regimen. In a subsequent trial (not included in the pooled analysis), outcomes with quetiapine and with placebo were comparable [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An open-label, six-week trial enrolled patients (n = 675) with unipolar major depression who, by history, did not respond to at least one antidepressant, and randomly assigned them to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         monotherapy (300 mg/day), add-on quetiapine (300 mg/day), or add-on
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (0.6 to 1.2 mmol/L) [
         <a href="#rid46">
          46
         </a>
         ]. Remission with quetiapine monotherapy, add-on quetiapine, and add-on lithium was comparable (24, 32, and 27 percent of patients). In addition, discontinuation of treatment due to adverse events appeared to be comparable for the three groups (12, 10, and 8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another trial compared
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         monotherapy with placebo for late-life unipolar depression. (See
         <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">
          "Diagnosis and management of late-life unipolar depression", section on 'Quetiapine monotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         However, the four trials in the pooled analysis used either fixed or semifixed doses, which may underestimate differences that are achieved with a flexible dose schedule that more closely reflects clinical practice [
         <a href="#rid83">
          83
         </a>
         ]. As an example, a subsequent randomized trial (also not included in the pooled analysis) using flexible doses compared
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release with placebo in older patients, and found a larger benefit than was seen in the pooled analysis. (See
         <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">
          "Diagnosis and management of late-life unipolar depression", section on 'Quetiapine monotherapy'
         </a>
         .)
        </p>
        <p>
         Although these findings indicate that
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release has some utility for major depression, ongoing concerns remain about safety issues and side effects, especially with long term treatment. Side effects observed in the randomized trials included dry mouth, sedation, dizziness, fatigue, increased appetite, weight gain, constipation, and blurred vision [
         <a href="#rid19">
          19-21,84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H95248726">
         <span class="h2">
          Other drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sulpiride appears to be effective for major depression, and amisulpride may be as well:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week randomized trial compared sulpiride (not available in the United States) with placebo as monotherapy in 171 patients with mild to moderate unipolar major depression [
         <a href="#rid85">
          85
         </a>
         ]. Reduction of depressive symptoms was significantly greater in patients who received sulpiride (mean dose 181 mg per day). The type and frequency of side effects were generally comparable, except that serum prolactin was abnormally high in 50 percent of the patients treated with sulpiride.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial found that amisulpride (50 mg per day) and
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         (20 mg per day) were comparable as monotherapy in 272 patients with unipolar major depression [
         <a href="#rid86">
          86
         </a>
         ]. However, the lack of a placebo arm and low fixed dose of both treatments undermine the trial’s validity.
        </p>
        <p>
        </p>
        <p>
         Sulpiride is not available in the United States (see
         <a class="drug drug_international" href="/z/d/drug information/138621.html" rel="external">
          "Sulpiride: International drug information (concise)"
         </a>
         ). Although amisulpride is available in the United States as an intravenous antiemetic, it is not available as an oral formulation for use in psychiatric disorders.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
         monotherapy may be as efficacious as antidepressant monotherapy for remission of unipolar major depression, but increases in prolactin and weight gain are greater with olanzapine than with antidepressants [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4118312670">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">
          "Society guideline links: Depressive disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21956323">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – In unipolar major depression, second-generation antipsychotics are indicated for patients with nonpsychotic depression that does not respond sufficiently to antidepressant monotherapy (the antipsychotic is generally added to the same antidepressant), as well as psychotic depression (the antipsychotic is started concurrently with an antidepressant). Also, second-generation antipsychotic monotherapy may be efficacious for nonpsychotic depressed patients. (See
         <a class="local">
          'Indications'
         </a>
         above and
         <a class="local">
          'Adjunctive treatment for nonpsychotic depression'
         </a>
         above and
         <a class="local">
          'Combination treatment for psychotic depression'
         </a>
         above and
         <a class="local">
          'Monotherapy for nonpsychotic depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acutely ill patients
         </strong>
         – The efficacy of
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         appear to be comparable for short-term augmentation of an antidepressant that has not adequately treated an episode of major depression. Much of the benefit occurs within the first two weeks of treatment. Adjunctive second-generation antipsychotics may be effective for patients with either a minimal response to antidepressant monotherapy or a partial response. Clinicians can select a particular antipsychotic based upon its secondary clinical effects. (See
         <a class="local">
          'Acute phase'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Remitted patients
         </strong>
         – For patients with unipolar major depression who have failed multiple treatment regimens and then responded to an adjunctive second-generation antipsychotic that is well tolerated, it is reasonable to continue the antipsychotic to prevent relapse. (See
         <a class="local">
          'Maintenance phase'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety issues
         </strong>
         – Safety issues with adjunctive second-generation antipsychotics include the metabolic syndrome, neuroleptic malignant syndrome (NMS), and tardive dyskinesia. (See
         <a class="local">
          'Safety issues'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Doses and adverse effects
         </strong>
         – The dose of an adjunctive second-generation antipsychotic for nonpsychotic unipolar major depression is often lower than the dose used for schizophrenia or bipolar disorder. Short-term use of adjunctive atypical antipsychotics for depression is usually well tolerated; however, adverse effects such as akathisia, weight gain, and sedation lead patients to discontinue treatment at significantly greater rates than placebo. (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009; 66:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Montgomery S, Papakostas GI, et al. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol 2013; 28:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lakoski JM, Aghajanian GK. Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 1985; 24:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64 Suppl 19:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008; 597:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33:2303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982; 4:173.
          </a>
         </li>
         <li class="breakAll">
          Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Treating Resistant Depression., Zohar J, Belmaker RH (Eds), PMA Publishing Corp, New York 1987. p.131.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Treatment of Patients with
Major Depressive Disorder, Third Edition, 2010. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 11, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8:67.
          </a>
         </li>
         <li class="breakAll">
          Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Clinical Practice Guideline 90, National Institute for Health &amp; Clinical Excellence http://guidance.nice.org.uk/CG90 (Accessed on June 06, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009; 14:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerhard T, Akincigil A, Correll CU, et al. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry 2014; 75:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31:2505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010; :CD008121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013; 10:e1001403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76:e487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papakostas GI, Fava M, Baer L, et al. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry 2015; 172:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016; 77:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:2404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010; 127:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010; 71:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pringsheim T, Gardner D, Patten SB. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ 2015; 350:h569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart TD, Hatch A, Largay K, et al. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis. J Affect Disord 2014; 162:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papakostas GI, Petersen TJ, Green C, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry 2005; 17:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Thase ME, Bellocchio EE, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol 2012; 27:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Rahman Z, Laubmeier KK, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS Spectr 2014; 19:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Dell'osso L, Kasper S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013; 151:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheon EJ, Lee KH, Park YW, et al. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. J Clin Psychopharmacol 2017; 37:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed S, Johnson GR, Chen P, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017; 318:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunner E, Tohen M, Osuntokun O, et al. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014; 39:2549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Thase ME, Trivedi MH, et al. Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009; 11:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2014; 44:2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Wisniewski SR, Thase ME, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol 2009; 29:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat 2011; 7:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Zhang P, Skuban A, et al. Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll BJ. Antipsychotic drugs for depression? Am J Psychiatry 2010; 167:216; author reply 216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009; 10:3061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisler RH, Khan A, Trivedi MH, et al. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. J Clin Psychiatry 2011; 72:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Citrome L. Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. J Clin Psychiatry 2011; 72:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010; 122:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamijima K, Higuchi T, Ishigooka J, et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 2013; 151:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Mischoulon D, Iosifescu D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji L, Pan S, Marti-Jaun J, et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002; 48:983.
          </a>
         </li>
         <li class="breakAll">
          HIGHLIGHTS OF PRESCRIBING INFORMATION (U.S. Food and Drug Adminsitration label). 12/2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204370s009lbl.pdf (Accessed on January 12, 2023).
         </li>
         <li class="breakAll">
          National Institute of Health, U.S. National Library of Medicine, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03738215 (Accessed on January 18, 2023).
         </li>
         <li class="breakAll">
          National Institute of Health, U.S. National Library of Medicine, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03739203 (Accessed on January 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007; 24:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shpaner A, Li W, Ankoma-Sey V, Botero RC. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008; 20:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004; 16:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naharci MI, Karadurmus N, Demir O, et al. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry 2011; 168:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC. Adjunctive Ziprasidone in Major Depression and the Current Status of Adjunctive Atypical Antipsychotics. Am J Psychiatry 2015; 172:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang G, McIntyre A, Earley WR, et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat 2014; 10:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004; 161:2045.
          </a>
         </li>
         <li class="breakAll">
          Earley W, McIntyre A, Wang G, et al. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). Presented at the 8th International Forum on Mood and Anxiety Disorder, Vienna, Austria, 12-14 November, 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rüther E, Degner D, Munzel U, et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 1999; 32:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassano GB, Jori MC, AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17:27.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14688 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816227" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : What happened to lithium? Antidepressant augmentation in clinical settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19687129" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652123" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23485955" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15358977" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Receptor mechanisms in the treatment of schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3158835" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14728084" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18831971" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942849" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18059438" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10193665" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pharmacological profile of neuroleptics at human monoamine transporters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127357" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Major tranquillisers used as antidepressants. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127357" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Major tranquillisers used as antidepressants. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992963" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992963" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992963" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17455102" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17455102" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19358790" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19668121" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20691481" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17074942" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24500284" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : National trends in second-generation antipsychotic augmentation for nonpsychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25069082" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8792761" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16760927" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21154393" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Second-generation antipsychotics for major depressive disorder and dysthymia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23554581" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919841" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26085041" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26301701" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26301771" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27046309" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26423182" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20884063" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592907" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17975181" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Risperidone for treatment-refractory major depressive disorder: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344725" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20361905" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25739588" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24766999" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16433058" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12363125" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22466058" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24642260" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23810357" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28129308" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28697253" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24801768" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20098527" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17335320" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262678" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593176" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21655344" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20123926" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Antipsychotic drugs for depression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14658950" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19954275" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19480467" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17541044" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Neuroleptic malignant syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20816039" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710853" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19358791" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21450157" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20675970" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24074484" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19407731" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22286203" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12089164" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12089164" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12089164" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12089164" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136647" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A novel augmentation strategy for treating resistant major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16259543" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17177199" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19047843" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Drug-induced liver injury: hepatotoxicity of quetiapine revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15618854" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Subfulminant liver failure associated with quetiapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21297052" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18681749" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18586273" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619770" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Adjunctive Ziprasidone in Major Depression and the Current Status of Adjunctive Atypical Antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24511235" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15514405" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15514405" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10505482" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11800503" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
